NO20054296L - Anvendelse av palonosetron for behandling av kvalme og oppkast etter kirurgisk inngrep - Google Patents

Anvendelse av palonosetron for behandling av kvalme og oppkast etter kirurgisk inngrep

Info

Publication number
NO20054296L
NO20054296L NO20054296A NO20054296A NO20054296L NO 20054296 L NO20054296 L NO 20054296L NO 20054296 A NO20054296 A NO 20054296A NO 20054296 A NO20054296 A NO 20054296A NO 20054296 L NO20054296 L NO 20054296L
Authority
NO
Norway
Prior art keywords
vomiting
palonosetron
treatment
nausea
surgery
Prior art date
Application number
NO20054296A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054296D0 (no
Inventor
Alberto Macciocch
Ricardo Braglia
Enrico Braglia
Luigi Baroni
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32908576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20054296(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of NO20054296D0 publication Critical patent/NO20054296D0/no
Publication of NO20054296L publication Critical patent/NO20054296L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20054296A 2003-02-18 2005-09-16 Anvendelse av palonosetron for behandling av kvalme og oppkast etter kirurgisk inngrep NO20054296L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44834203P 2003-02-18 2003-02-18
PCT/EP2004/001558 WO2004073714A1 (en) 2003-02-18 2004-02-18 Use of palonosetron treating post-operative nausea and vomiting

Publications (2)

Publication Number Publication Date
NO20054296D0 NO20054296D0 (no) 2005-09-16
NO20054296L true NO20054296L (no) 2005-11-17

Family

ID=32908576

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054296A NO20054296L (no) 2003-02-18 2005-09-16 Anvendelse av palonosetron for behandling av kvalme og oppkast etter kirurgisk inngrep

Country Status (31)

Country Link
US (1) US20060074101A1 (https=)
EP (2) EP1596862B1 (https=)
JP (1) JP2006517944A (https=)
KR (1) KR101113087B1 (https=)
CN (1) CN1750822A (https=)
AT (1) ATE490774T1 (https=)
AU (1) AU2004212704B2 (https=)
BR (1) BRPI0407549A (https=)
CA (1) CA2515946C (https=)
CU (1) CU23587B7 (https=)
CY (1) CY1111312T1 (https=)
DE (1) DE602004030424D1 (https=)
DK (1) DK1596862T3 (https=)
EA (1) EA013836B1 (https=)
EC (1) ECSP055970A (https=)
ES (1) ES2357769T3 (https=)
GE (1) GEP20104908B (https=)
HR (1) HRP20050709A2 (https=)
IS (1) IS7983A (https=)
MX (1) MXPA05008757A (https=)
MY (1) MY143789A (https=)
NO (1) NO20054296L (https=)
NZ (1) NZ541862A (https=)
PL (1) PL378122A1 (https=)
PT (1) PT1596862E (https=)
SI (1) SI1596862T1 (https=)
TW (1) TWI355936B (https=)
UA (1) UA96254C2 (https=)
UY (1) UY28193A1 (https=)
WO (1) WO2004073714A1 (https=)
ZA (1) ZA200506580B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10393729T5 (de) * 2002-11-15 2005-10-13 Helsinn Healthcare S.A. Verfahren zur Behandlung von Emesis
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
CN101410094B (zh) * 2006-01-27 2013-04-17 阿普塔利斯制药股份有限公司 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统
KR20140088230A (ko) * 2006-01-27 2014-07-09 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템
KR101441459B1 (ko) * 2006-10-24 2014-09-18 헬신 헬쓰케어 에스.에이. 안정성 및 생체이용률이 개선된 염산 팔로노세트론을 포함하는 연질 캡슐
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
US20090155363A1 (en) * 2007-12-14 2009-06-18 Todd Maibach Methods for oral administration of active drugs
EP2286814B1 (en) 2008-05-15 2013-10-16 Hisamitsu Pharmaceutical Co., Inc. Transdermal preparation containing palonosetron
EP2364138A2 (en) * 2008-12-08 2011-09-14 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
DK2432467T3 (en) 2009-05-20 2018-04-16 Inst Nat Sante Rech Med SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS FOR USE IN TREATMENT OF VESTIBULAR DAMAGE LESSONS
ES2432618T3 (es) * 2009-05-20 2013-12-04 Inserm (Institut National De La Santé Et De La Recherche Medicale) Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
CN102781939A (zh) 2009-11-13 2012-11-14 赫尔辛医疗股份公司 帕洛诺司琼代谢物
ES2623503T3 (es) 2009-11-18 2017-07-11 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos mediados centralmente
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
KR101368587B1 (ko) * 2010-12-27 2014-03-05 주식회사 삼양바이오팜 오심 또는 구토 방지용 조성물
WO2014004126A1 (en) 2012-06-26 2014-01-03 Fleming C Andrew Treating postoperative nausea and vomiting
CN105934247A (zh) 2013-12-23 2016-09-07 株式会社三养生物制药 包含帕洛诺司琼的药物组合物
MX384045B (es) 2016-04-14 2025-03-14 Sensorion (+)-azasetrón para su uso en el tratamiento de trastornos del oído.
JP6768404B2 (ja) * 2016-08-12 2020-10-14 武田テバファーマ株式会社 パロノセトロン又はその薬学的に許容される塩を含む医薬組成物
JP6705348B2 (ja) * 2016-09-23 2020-06-03 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
KR101802183B1 (ko) * 2016-11-16 2017-11-28 주식회사 유영제약 팔로노세트론을 활성성분으로 함유하는 약제학적 조성물
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
HRP20230471T1 (hr) 2018-01-12 2023-07-21 Orion Corporation Palonsetron kapi za oči za liječenje ili prevenciju mučnine i povraćanja
CN108703960A (zh) * 2018-07-25 2018-10-26 无锡鑫连鑫生物医药科技有限公司 一种帕洛诺司琼缓释微球及其制备方法和使用方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US4937247A (en) 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
DE3650772T2 (de) 1985-04-27 2003-04-03 F. Hoffmann-La Roche Ag, Basel Derivate von Indazole-3-carboxamide und -3-carboxylsäure
US5240954A (en) 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
GB8516083D0 (en) 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5578628A (en) 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
US4906755A (en) 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US4707484A (en) 1986-11-25 1987-11-17 Hoffmann-La Roche Inc. Substituted piperidinomethylindolone and cyclopent(b)indolone derivatives
US5011846A (en) 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
PL166267B1 (pl) 1989-11-28 1995-04-28 Syntex Inc Sposób wytwarzania nowych zwiazków trójpierscieniowych PL PL PL PL
US5189041A (en) 1990-11-16 1993-02-23 Syntex (U.S.A.) Inc. Tricyclic 5-ht3 receptor antagonists
US5137893A (en) 1991-03-07 1992-08-11 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5491148A (en) 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
GB9305593D0 (en) 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
US5492914A (en) 1994-07-28 1996-02-20 Syntex (U.S.A.) Inc. 2-(1-azabicyclo[2.2.2]oct-3 s-yl)-6-hydroxy-2,4,5,6-tetrahydro-1H-benz[DE]is[2.2.2]oct-3's-yl)-6-hydroxy-2,3,3a,4,5,6-hexahydro-1h-benz [DE]isoquinolin-1-one and individual stereoisomers thereof
GB9423588D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US6294548B1 (en) 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
AU4551499A (en) * 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5-HT3 receptors
BR9914799A (pt) * 1998-10-27 2001-07-10 Alcon Lab Inc Sistema conservante para composições farmacêuticas administráveis topicamente contendo um sabão de ácido graxo/aminoácido
US6196963B1 (en) * 1999-03-02 2001-03-06 Medtronic Ave, Inc. Brachytherapy device assembly and method of use
WO2003100091A1 (en) * 2002-05-24 2003-12-04 Epidauros Biotechnologie Ag Means and methods for improved treatment using 'setrones'
DE10393729T5 (de) * 2002-11-15 2005-10-13 Helsinn Healthcare S.A. Verfahren zur Behandlung von Emesis
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
US8598219B2 (en) * 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron

Also Published As

Publication number Publication date
DE602004030424D1 (de) 2011-01-20
EP2258367A2 (en) 2010-12-08
CY1111312T1 (el) 2015-08-05
DK1596862T3 (da) 2011-03-28
ES2357769T3 (es) 2011-04-29
SI1596862T1 (sl) 2011-03-31
PL378122A1 (pl) 2006-03-06
TW200418474A (en) 2004-10-01
EA013836B1 (ru) 2010-08-30
EP1596862A1 (en) 2005-11-23
IS7983A (is) 2005-08-15
HK1076402A1 (en) 2006-01-20
AU2004212704A1 (en) 2004-09-02
AU2004212704B2 (en) 2009-10-01
WO2004073714A1 (en) 2004-09-02
JP2006517944A (ja) 2006-08-03
EA200501318A1 (ru) 2006-02-24
CU23587B7 (es) 2010-10-30
MY143789A (en) 2011-07-15
UY28193A1 (es) 2004-09-30
KR20050121671A (ko) 2005-12-27
CA2515946A1 (en) 2004-09-02
EP1596862B1 (en) 2010-12-08
ATE490774T1 (de) 2010-12-15
ECSP055970A (es) 2006-01-16
TWI355936B (en) 2012-01-11
NZ541862A (en) 2008-04-30
MXPA05008757A (es) 2006-05-31
PT1596862E (pt) 2011-03-15
EP2258367A3 (en) 2011-07-13
HRP20050709A2 (en) 2005-12-31
BRPI0407549A (pt) 2006-02-14
UA96254C2 (uk) 2011-10-25
GEP20104908B (en) 2010-03-10
NO20054296D0 (no) 2005-09-16
KR101113087B1 (ko) 2012-02-15
CA2515946C (en) 2008-12-02
US20060074101A1 (en) 2006-04-06
ZA200506580B (en) 2006-06-28
CN1750822A (zh) 2006-03-22

Similar Documents

Publication Publication Date Title
NO20054296L (no) Anvendelse av palonosetron for behandling av kvalme og oppkast etter kirurgisk inngrep
UA87473C2 (en) Muscarinic acetycholine receptor antagonists
NO20080484L (no) Niacin-reseptorantagonister, preparater inneholdende slike forbindelser og behandlingsmetoder
DE602006007556D1 (de) Heteroarylsulfonylstilbene als 5-ht2a-antagonisten
CL2010000204A1 (es) Compuestos intermediarios derivados de 4 amino-3-metoxibenzamida; compuesto intermediario n-{4-[4-(ciclopropilmetil)piperazin-1-il]ciclohexil}acetamida; compuesto intermediario 2-cloro-7-etil-7,8-dihidro-5-metil-8-(1-metiletil)-6(5h)-pteridinona, útiles en la preparación de dihidropteridinonas sustituidas (divisional sol. 2077-05).
IS7319A (is) Fjölgervingar klópídógrelvetnissúlfats
DE602005012634D1 (en) Arylsulfonylnaphthalinderivate als 5ht2a-antagonisten
EA200800716A1 (ru) Новая кристаллическая форма производного пиридазино[4,5-в]индола
BRPI0512958A (pt) antagonistas de nk1
NO20063032L (no) Nye M3 muskarinacetylkolinreceptorantagoniser
MA27566A1 (fr) Inhibiteurs de 4-oxo-1-(3-phenyle substitue -1, 4-dihydro-1, 8-naphthyridine-3-carboxamide phosphodiesterase-4
NO20061112L (no) Metode og apparat for kinematisk linking av multiple seismiske domener
NO20060775L (no) Muskarine acetylkolinreseptorantagonister
CA2505990A1 (en) Palonosetron for the treatment of chemotherapy-induced emesis
NO20072832L (no) Smertestillende middel
TW200744593A (en) Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery
MX2007005428A (es) Combinaciones de agonistas del receptor nicotinico alfa 7 y de la acetilcolina.
PL1831152T3 (pl) Pochodne tetraliny i indanu oraz ich zastosowanie jako antagonistów 5-HT
WO2005000291A8 (en) Method for treatment of idiopathic pulmonary fibrosis using triptolide derivatives
DE60102231D1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
DK1776366T3 (da) Immunomodulerende oxopyrazolocinnoliner som CD80-inhibitorer
MX2007007485A (es) Derivados de cromano y usos de los mismos en el tratamiento de trastornos del sistema nervioso central.
RU2004107084A (ru) Способ лечения рецидивирующего птеригиума
MXPA04004071A (es) Metodo para tratamiento de vejiga hiperactiva.
WO2003080118A3 (en) Combination of an aldosterone receptor antagonist and a fibric acid derivative